First Time Loading...

Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 3.215 CHF -4.03% Market Closed
Updated: May 8, 2024

Molecular Partners AG
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Molecular Partners AG
Revenue Peer Comparison

Comparables:
ADCT
CRSP
BSLN
IDIA
KURN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Revenue
CHf7m
CAGR 3-Years
-9%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Revenue
$69.6m
CAGR 3-Years
N/A
CAGR 5-Years
129%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Revenue
$371.2m
CAGR 3-Years
709%
CAGR 5-Years
160%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Revenue
CHf157.6m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
14%
Idorsia Ltd
SIX:IDIA
Revenue
CHf97.1m
CAGR 3-Years
60%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Revenue
CHf33.6m
CAGR 3-Years
103%
CAGR 5-Years
116%
CAGR 10-Years
N/A

See Also

What is Molecular Partners AG's Revenue?
Revenue
7m CHF

Based on the financial report for Dec 31, 2023, Molecular Partners AG's Revenue amounts to 7m CHF.

What is Molecular Partners AG's Revenue growth rate?
Revenue CAGR 5Y
-7%

Over the last year, the Revenue growth was -96%. The average annual Revenue growth rates for Molecular Partners AG have been -9% over the past three years , -7% over the past five years .